Helicobacter

Papers
(The TQCC of Helicobacter is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
ArticleCitations
The effect of antibiotic resistance on Helicobacter pylori eradication efficacy: A systematic review and meta‐analysis62
Review: Epidemiology of Helicobacter pylori50
Review: Extragastric diseases andHelicobacter pylori43
A meta‐analysis of the association between Helicobacter pylori infection and risk of atherosclerotic cardiovascular disease40
A comparative study of 14‐day dual therapy (esomeprazole and amoxicillin four times daily) and triple plus bismuth therapy for first‐line Helicobacter pylori infection eradication: A randomized40
Review: Pathogenesis of Helicobacter pylori infection39
The impact of Helicobacter pylori infection, eradication therapy, and probiotics intervention on gastric microbiota in young adults38
Review: Diagnosis of Helicobacter pylori infection35
Changes in the human gut microbiota composition caused by Helicobacter pylori eradication therapy: A systematic review and meta‐analysis35
PCR analysis and specific immunohistochemistry revealing a high prevalence of non‐Helicobacter pylori Helicobacters in Helicobacter pylori‐negative gastric disease patients in Japan: Hig34
Optimization of vonoprazan‐amoxicillin dual therapy for eradicating Helicobacter pyloriinfection in China: A prospective, randomized clinical pilot study34
Review – Treatment of Helicobacter pylori infection 202034
Time trends and other sources of variation in Helicobacter pylori infection in mainland China: A systematic review and meta‐analysis33
Helicobacter pylori induced reactive oxygen Species: A new and developing platform for detection29
Effects of non‐viableLactobacillus reutericombining with 14‐day standard triple therapy onHelicobacter pylorieradication: A randomized double‐blind placebo‐controlled trial28
PPI‐amoxicillin dual therapy four times daily is superior to guidelines recommended regimens in the Helicobacter pylori eradication therapy within Asia: A systematic review and meta‐analysis26
Gastric microbiota and Helicobacter pylori in Indonesian population25
Re‐assessment of the disk diffusion technique for routine antimicrobial susceptibility testing for Helicobacter pylori23
An overview of traditional Chinese medicine therapy for Helicobacter pylori–related gastritis23
Evaluation of the Allplex™ H pylori and ClariR PCR Assay for Helicobacter pylori detection on gastric biopsies23
Efficacy and safety of a new rifabutin‐based triple therapy with vonoprazan for refractoryHelicobacter pyloriinfection: A prospective single‐arm study22
Helicobacter pylori eradication therapy outcome according to clarithromycin susceptibility testing in Japan22
Long‐term changes in the gut microbiota after 14‐day bismuth quadruple therapy in penicillin‐allergic children22
The efficacy of Helicobacter pylori eradication in diabetics and its effect on glycemic control: A systematic review and meta‐analysis22
The appropriate cutoff gastric pH value for Helicobacter pylori eradication with bismuth‐based quadruple therapy21
Helicobacter pylori infection and eradication: Exploring their impacts on the gastrointestinal microbiota21
A panel of stomach‐specific biomarkers (GastroPanel®) for the diagnosis of atrophic gastritis: A prospective, multicenter study in a low gastric cancer incidence area20
Helicobacter pylori induces gastric cancer via down‐regulating miR‐375 to inhibit dendritic cell maturation20
CRISPR‐based detection of Helicobacter pylori in stool samples20
The efficacy of Lactobacillus acidophilus and rhamnosus in the reduction of bacterial load of Helicobacter pylori and modification of gut microbiota—a double‐blind, placebo‐controlled, randomiz20
Transporters HP0939, HP0497, and HP0471 participate in intrinsic multidrug resistance and biofilm formation in Helicobacter pylori by enhancing drug efflux20
Impact of smoking on the eradication of Helicobacter pylori20
Eradication rates of Helicobacter pylori in treatment‐naive patients following 14‐day vonoprazan‐amoxicillin dual therapy: A multicenter randomized controlled trial in China20
Efficacy of eradication therapy in Helicobacter pylori‐negative gastric mucosa‐associated lymphoid tissue lymphoma: A meta‐analysis19
Triple‐nanostructuring‐based noninvasive electro‐immune sensing of CagA toxin for Helicobacter pylori detection19
Oral multivalent epitope vaccine, based on UreB, HpaA, CAT, and LTB, for prevention and treatment of Helicobacter pylori infection in C57BL / 6 mice19
Impact of body size on first‐line Helicobacter pylori eradication success using vonoprazan and amoxicillin dual therapy19
Probiotics mitigate Helicobacter pylori‐induced gastric inflammation and premalignant lesions in INS‐GAS mice with the modulation of gastrointestinal microbiota18
Advantage of 16S rRNA amplicon sequencing in Helicobacter pylori diagnosis18
Awareness and attitudes regarding Helicobacter pylori infection in Chinese physicians and public population: A national cross‐sectional survey18
Effects of sodium butyrate supplementation on inflammation, gut microbiota, and short‐chain fatty acids in Helicobacter pylori‐infected mice18
Effects of enhanced education for patients with the Helicobacter pylori infection: A systematic review and meta‐analysis18
Helicobacter pylori infection is associated with the co‐occurrence of bacteria in the oral cavity and the gastric mucosa17
Need for standardization and harmonization of Helicobacter pylori antimicrobial susceptibility testing17
Helicobacter pylori infection and the progression of atherosclerosis: A systematic review and meta‑analysis17
Whole family—based Helicobacter pylori eradication is a superior strategy to single‐infected patient treatment approach: A systematic review and meta‐analysis16
Transmission of Helicobacter pylori between a human and two dogs: A case report16
Diagnosis and treatment of Helicobacter pylori infection by physicians in China: A nationwide cross‐sectional study15
Prevalence and risk factors of Helicobacter pylori infection in Wuwei, a high‐risk area for gastric cancer in northwest China: An all‐ages population‐based cross‐sectional study15
Eradication rate and safety of a “simplified rescue therapy”: 14‐day vonoprazan and amoxicillin dual regimen as rescue therapy on treatment of Helicobacter pylori infection previously failed in15
Association between bacteria other than Helicobacter pylori and the risk of gastric cancer15
Bismuth quadruple regimen with tetracycline or doxycycline versus three‐in‐one single capsule as third‐line rescue therapy for Helicobacter pylori infection: Spanish data of the European Hel15
Rabeprazole‐amoxicillin dual therapy as first‐line treatment for H pylori eradication in special patients: A retrospective, real‐life study15
Review: Other Helicobacter species15
Quadruple therapy with vonoprazan 20 mg daily as a first‐line treatment for Helicobacter pylori infection: A single‐center, open‐label, noninferiority, randomized controlled trial15
Combinations of antibiotics and vonoprazan for the treatment of Helicobacter pylori infections—Exploratory study15
Survey of the antimicrobial resistance of Helicobacter pylori in France in 2018 and evolution during the previous 5 years15
Influence of Helicobacter pylori infection on PD‐1/PD‐L1 blockade therapy needs more attention15
The recurrence rate ofHelicobacter pyloriin recent 10 years: A systematic review and meta‐analysis14
The effect of previous eradication failure on antibiotic resistance of Helicobacter pylori: A retrospective study over 8 years in Beijing14
Helicobacter pylori and the intestinal microbiome among healthy school‐age children14
Associations between Helicobacter pylori with nonalcoholic fatty liver disease and other metabolic conditions in Guatemala14
10‐Day and 14‐day high‐dose dual therapy for the treatment of Helicobacter pylori: A propensity score matching analysis14
Prevalence, clinical features, and esophagogastroduodenoscopy (EGD) findings of non‐Helicobacter pylori Helicobacter infection: A study of 50 cases at a single facility in Japan14
Association between Helicobacter pylori infection and growth outcomes in children: A meta‐analysis14
Application of WeChat platform in the management of patients infected with Helicobacter pylori14
Susceptibility‐guided therapy for Helicobacter pylori‐infected penicillin‐allergic patients: A prospective clinical trial of first‐line and rescue therapies13
Dendritic cell‐derived TGF‐β mediates the induction of mucosal regulatory T‐cell response to Helicobacter infection essential for maintenance of immune tolerance in mice13
Helicobacter pylori adhesins: HpaA a potential antigen in experimental vaccines for H. pylori13
Review: Helicobacter pylori infection in children13
Immune evaluation of aSaccharomyces cerevisiae‐based oral vaccine againstHelicobacter pyloriin mice13
Eradication of Helicobacter pylori infection decreases risk for dyslipidemia: A cohort study13
Searching for an optimal therapy for H pylori eradication: High‐dose proton‐pump inhibitor dual therapy with amoxicillin vs. standard triple therapy for 14 days13
Pepsinogen II in gastritis and Helicobacter pylori infection13
Lactobacillus rhamnosus JB3 inhibits Helicobacter pylori infection through multiple molecular actions13
Extracellular vesicles from helicobacter pylori‐infected cells and helicobacter pylori outer membrane vesicles in atherosclerosis13
Gastric organoids: Advancing the study of H. pylori pathogenesis and inflammation12
Long term impact of vonoprazan‐based Helicobacter pylori treatment on gut microbiota and its relation to post‐treatment body weight changes12
Rabeprazole plus amoxicillin dual therapy is equally effective to bismuth‐containing quadruple therapy for Helicobacter pylori eradication in central China: A single‐center, prospective, open‐l12
Dynamic changes in antibiotic resistance genes and gut microbiota after Helicobacter pylori eradication therapies12
Association betweenHelicobacter pyloriantibodies determined by multiplex serology and gastric cancer risk: A meta‐analysis12
Helicobacter pylori infection and risk of cardiovascular disease12
Adherence to Maastricht V/Florence consensus report for the management ofHelicobacter pyloriinfection among primary care physicians and medical students in Croatia: A cross‐sectional study12
Transmission routes and patterns of helicobacter pylori11
Economic and health impacts of introducing Helicobacter pylori eradication strategy into national gastric cancer policy in Japan: A cost‐effectiveness analysis11
Cardia and non‐cardia gastric cancer risk associated with Helicobacter pylori in East Asia and the West: A systematic review, meta‐analysis, and estimation of population attributable fraction11
Helicobacter pylori infection prevalence in ambulatory settings in 2017–2019 in RUSSIA: The data of real‐world national multicenter trial11
Helicobacter pylori and cardiovascular risk: Only a dead Helicobacter is a good Helicobacter?11
Perspectives from recent advances of Helicobacter pylori vaccines research11
Tetracycline‐levofloxacin versus amoxicillin‐levofloxacin quadruple therapies in the second‐line treatment of Helicobacter pylori infection10
“True” Helicobacter pylori infection and non‐cardia gastric cancer: A pooled analysis within the Stomach Cancer Pooling (StoP) Project10
Application of molecular techniques inHelicobacter pyloridetection: limitations and improvements10
Unraveling antimicrobial resistance in Helicobacter pylori: Global resistome meets global phylogeny10
Long‐term changes in the gut microbiota after triple therapy, sequential therapy, bismuth quadruple therapy and concomitant therapy for Helicobacter pylori eradication in Chinese children10
Effect of enhanced patient instructions onHelicobacter pylorieradication: A systematic review and meta‐analysis of randomized controlled trials10
Long noncoding RNA NEAT1 promotes tumorigenesis in H. pylori gastric cancer by sponging miR‐30a to regulate COX‐2/BCL9 pathway10
Investigation of endoscopic findings in nine cases of Helicobacter suis‐infected gastritis complicated by gastric mucosa‐associated lymphoid tissue lymphoma10
Helicobacter pylori infection and risk of multiple sclerosis: An updated meta‐analysis9
Efficacy and safety of bismuth‐based quadruple therapy forHelicobacterpylorieradication in children9
Review: Prevention and management of gastric cancer9
Clinical and economic impact of “triple therapy” for Helicobacter pylori eradication on peptic ulcer disease in Australia9
A comparative whole genome analysis of Helicobacter pylori from a human dense South Asian setting9
CRHP Finder, a webtool for the detection of clarithromycin resistance in Helicobacter pylori from whole‐genome sequencing data9
Prevalence and trends of multiple antimicrobial resistance of Helicobacter pylori in one tertiary hospital for 20 years in Korea9
Economic and health impacts of Helicobacter pylori eradication strategy for the treatment of peptic ulcer disease: A cost‐effectiveness analysis9
Doxycycline and minocycline inHelicobacter pyloritreatment: A systematic review and meta‐analysis9
Integrative proteomic and metabolomic analyses reveal the mechanism by which bismuth enables Helicobacter pylori eradication9
Does technology‐enhanced communication improve Helicobacter pylori eradication outcomes?—A meta‐analysis9
Review ‐ Helicobacter pylori and non‐malignant upper gastro‐intestinal diseases9
Cholesterol glucosylation–based survival strategy in Helicobacter pylori9
Helicobacter pylori infection modulates endogenous hydrogen sulfide production in gastric cancer AGS cells9
Prevalence estimates of Helicobacter species infection in pancreatic and biliary tract cancers9
0.029217958450317